Market Research Logo

Global Rheumatoid Arthritis Drugs Market 2016-2020

About Rheumatoid Arthritis Drugs

RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, NSAIDs, corticosteroids, and analgesics are being developed and administered to treat individuals with RA.

Technavio’s analysts forecast the global RA drugs market to grow at a CAGR of 3.43% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global RA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat the disease.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Rheumatoid Arthritis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb (BMS)
  • Johnson & Johnson
  • Pfizer
  • F. Hoffmann-La Roche
Other prominent vendors
  • Ablynx
  • Alder BioPharmaceuticals
  • Antares Medical Services
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Celltrion
  • ChemoCentryx
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Incyte
  • KaloBios Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Merck
  • Morphotek
  • Novo Nordisk
  • Regeneron Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Takeda Pharmaceuticals
  • UCB
  • Vertex Pharmaceuticals
Market driver
  • Growing older population
  • For a full, detailed list, view our report
Market challenge
  • Increasing costs of biologicals
  • For a full, detailed list, view our report
Market trend
  • Emergence of biosimilars
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Rheumatoid Arthritis Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Rheumatoid Arthritis Drugs Market: AbbVie, Amgen, Bristol-Myers Squibb (BMS), Johnson & Johnson, Pfizer and F. Hoffmann-La Roche

Other Prominent Vendors in the market are: Ablynx, Alder BioPharmaceuticals, Antares Medical Services, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Morphotek, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Takeda Pharmaceuticals, UCB and Vertex Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “It is expected that the availability of patient assistance programs from governmental and non-governmental organizations to bode well for the market. These programs help decrease the churn out rate of the patients seeking treatment by reducing the out-of-pocket expenditure of consumers.”

According to the report, the number of older people with RA due to age-related joint disorders is rising in both developing and developed countries. This is expected to create more demand for RA drugs. The market dominance of biologics is also expected to drive market growth during the forecast period.

Further, the report states that the high cost of treatments for RA; however, hinders the acceptability of available treatments among patients.

Companies Mentioned

AbbVie, Amgen, Bristol-Myers Squibb (BMS), Johnson & Johnson, Pfizer, F. Hoffmann-La Roche, Ablynx, Alder BioPharmaceuticals, Antares Medical Services, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Morphotek, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Takeda Pharmaceuticals, UCB, Vertex Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Assumptions
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key buying criteria for RA drugs
  • Disease overview
    • Understanding RA
      • Table Classification of RA based on disease severity
      • Table Classification of RA based on disease severity 2016
    • Etiology and pathophysiology
      • Table Etiology and pathophysiology of RA
    • Signs and symptoms
      • Table Signs and symptoms of RA
    • Diagnosis
      • Table Diagnostic tests for RA
    • Disease management
      • Table Treatment options for RA
      • Table Non-pharmacological therapies used for RA
      • Table Pharmacotherapy therapy for RA
      • Table Drugs used to treat RA
      • Table Classification of surgical treatment for RA
      • Table Percentage share of treatment of RA 2016
      • Table Historical milestones in treatment of RA
      • Table Treatment algorithm for RA
    • Economic burden of RA
      • Table Economic burden of RA
      • Table Annual treatment costs of RA within Europe and US 2015 ($)
      • Table Cost difference between biological DMARDs and non-biological DMARDs
    • Epidemiology
      • Table Projected prevalence of RA in Americas 2010-2030 ($ millions)
      • Table New cases of RA in UK per year 2016
      • Table Existing cases of RA in UK
  • Impact of biologics in RA
    • Table Impact of biologics on various sectors
  • Pipeline portfolio
    • Table Pipeline molecules for RA
    • Novel mechanisms targeted by pipeline candidates
      • Table Novel targets of pipeline candidates
      • Table Candidates under development: Baricitinib
      • Table Candidates under development: Decernotinib
      • Table Candidates under development: CCX354
      • Table Candidates under development: Sirukumab
      • Table Candidates under development: Infliximab biosimilar
      • Table Candidates under development: Secukinumab
      • Table Candidates under development: Bimekizumab
    • Clinical trials for RA
      • Table Clinical trials of RA drugs by phase 2016
      • Table Clinical trials of RA drugs by status 2016
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global RA drugs market 2015-2020 ($ billions)
      • Table Opportunities in RA drugs industry
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global RA drugs market segmentation by drug class
    • DMARDs
      • Table Examples of non-biologic DMARDs and biologic DMARDs for RA
    • NSAIDs
      • Table NSAIDs used to treat RA
    • Corticosteroids
    • Analgesics
    • Others
      • Table Market share of global RA drugs market by drug class 2015
    • Global DMARDs market
      • Table Global DMARDs market 2015-2020 ($ billions)
    • Global NSAIDs market
      • Table Global NSAIDs market 2015-2020 ($ billions)
    • Global corticosteroids market
      • Table Global corticosteroids market 2015-2020 ($ billions)
    • Global analgesics market
      • Table Global analgesics market 2015-2020 ($ billions)
  • Market segmentation by MOA
    • Table Market segmentation of global RA drugs market by MOA
    • TNF inhibitors
      • Table Mean percentage of patients receiving TNF inhibitors 2010 and 2015
    • IL-1 blockers
    • JAK inhibitors
    • Selective costimulation modulators
      • Table Global RA drugs market share by MOA 2015
  • Market segmentation by type of molecule
    • Table Global RA drugs market segmentation by type of molecule
    • Biologics
    • Small molecules
      • Table Global RA drugs market share by type of molecules 2015
  • Market segmentation by ROA
    • Table Global RA drugs market segmentation by ROA
    • Oral
    • Parenteral
    • Topical
      • Table Global RA drugs market segmentation by ROA 2015
  • Market segmentation by dosage form
    • Table Global RA drugs market segmentation by dosage form
    • Solid
    • Liquid
    • Semi-solid
      • Table Global RA drugs market segmentation by dosage form 2015
  • Geographical segmentation
    • Table Global RA drugs by geography 2015
    • Table Global RA drugs market by geography 2015-2020 ($ billions)
    • Table Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
    • RA drugs market in Americas
      • Table RA drugs market in Americas 2015-2020 ($ billions)
      • Table RA drugs market in Americas by country 2015
    • RA drugs market in US
      • Table RA drugs market in US 2015-2020 ($ billions)
      • Table RA drugs sales in US by drug class 2015
      • Table Drivers and challenges of RA drugs market in US
    • RA drugs market in EMEA
      • Table RA drugs market in EMEA 2015-2020 ($ billions)
      • Table RA drugs market in EMEA by country 2015
      • Table RA sales in EMEA by drug class 2015
    • RA drugs market in Germany
      • Table RA drugs market in Germany 2015-2020 ($ billions)
    • RA drugs market in UK
      • Table RA drugs market in UK 2015-2020 ($ billions)
    • RA drugs market in Spain
      • Table RA drugs market in Spain 2015-2020 ($ millions)
    • RA drugs market in Italy
      • Table RA drugs market in Italy 2015-2020 ($ millions)
    • RA drugs market in France
      • Table RA drugs market in France 2015-2020 ($ millions)
    • Rheumatoid arthritis drugs market in APAC
      • Table RA drugs market in APAC 2015-2020 ($ billions)
      • Table RA drugs market in APAC by country 2015
    • RA drugs market in Japan
      • Table RA drugs market in Japan 2015-2020 ($ billions)
      • Table RA drugs sales in Japan by drug class 2015
      • Table Drivers and challenges to growth of RA drugs market in Japan
    • RA drugs market in Australia
      • Table RA drugs market in Australia 2015-2020 ($ millions)
      • Table RA drugs sales in Australia by drug class 2015
      • Table Drivers and challenges in RA drugs market in Australia
    • RA drugs market in India
      • Table RA drugs market in India 2015-2020 ($ billions)
      • Table RA sales in India by drug class 2015
    • RA drugs market in China
      • Table RA drugs market in China 2015-2020 ($ millions)
      • Table RA drugs sales in China by drug class 2015
  • Key leading countries
    • Table Key leading countries
  • Market drivers
    • Growing older population
      • Table Population aged 60 years and over: World, developed and developing regions ($ millions)
    • Market dominance of biologics
      • Table FDA approval of biologicals
    • Promising drug pipeline
      • Table List of pipeline molecules
    • Changing lifestyle patterns
      • Table Lifestyle factors - Risk of rheumatoid arthritis
    • Advances in diagnosis technology
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Increasing costs of biologicals
      • Table Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
    • Loss of patent exclusivity of branded therapies
      • Table Approval and patent expiries of top selling biologics
    • Use of complementary and alternative medicines (CAMs)
      • Table CAM therapies for RA
      • Table Usage of CAM in US
    • Adverse effects of drugs
      • Table Side effects associated with RA
    • Stringent regulations
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of biosimilars
    • Patient assistance programs
      • Table Patient assistance programs offered by companies
    • Popularity of off-label and traditional treatment options
    • Strategic alliances
    • Increase in public awareness
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Revenue share of RA drugs by vendors 2015
      • Table YoY sales comparison of top drugs 2012-2014 ($ billions)
      • Table Competitive assessment of top RA drugs
      • Table Revenue share of RA drugs 2015
    • AbbVie
      • Table AbbVie: Product segmentation by revenue 2014
      • Table AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
      • Table Sales of Humira in major markets
      • Table AbbVie: SWOT analysis
    • Amgen
      • Table Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
      • Table Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
      • Table Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
      • Table Amgen: SWOT analysis
    • BMS
      • Table BMS: Segmentation by revenue 2014
      • Table BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
      • Table BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
      • Table BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
      • Table Orencia sales for RA in major markets 2014
      • Table BMS: SWOT analysis
    • F. Hoffmann-La Roche
      • Table RA products by revenue 2014
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
      • Table MabThera/Rituxan geographic segmentation by revenue 2014
      • Table F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
      • Table Actemra/RoActemra geographic segmentation by revenue 2014
      • Table F. Hoffmann-La Roche: SWOT analysis
    • Johnson & Johnson
      • Table Johnson & Johnson: Segmentation of key drugs 2014
      • Table Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
      • Table Johnson & Johnson: SWOT analysis
    • Pfizer
      • Table Pfizer: Rhematoid drugs product segmentation by revenue 2014
      • Table Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
      • Table Pfizer: SWOT analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report